BLRX BioLineRx Ltd.

1.08
+0.01  (1%)
Previous Close 1.07
Open 1.08
Price To book 1.96
Market Cap 112429661
Shares 104,101,538
Volume 201,508
Short Ratio 0.62
Av. Daily Volume 682,019

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2 trial initiation announced July 10, 2017.
BL-8040 in combination with TECENTRIQ (atezolizumab)
Pancreatic cancer
Phase 2a trial initiation announced January 17, 2017.
BL-8040 in combination with KEYTRUDA
Pancreatic cancer
Phase 2 initiated September 2016. Partial data due 2H 2017. Full data due 2H 2018.
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
Development plans to be released by early 2017.
BL-7010
Gluten sensitivity
Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
BL-8040
Consolidation treatment for AML cancer patients
Phase 2 trial initiated March 2016. Partial data released March 20, 2017 with topline results by the end of 2017 with Phase 2/3 trial to be initiated 2H 2017.
BL-8040
Mobilization and collection of bone marrow stem cells
Phase 2 data released March 2016. Full set of data presented September 8, 2016
BL-8040
Acute myeloid leukemia (AML) cancer relapsed and refractory

Latest News

  1. BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York
  2. BioLineRx Moves a Regulatory Submission for BL-8040 Trial
  3. BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization
  4. Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call
  5. BioLineRx Reports Second Quarter 2017 Financial Results
  6. BioLineRx to Report Second Quarter 2017 Results on August 8, 2017
  7. 4 Biotech Stocks to Watch This Quarter
  8. 3 Biotech Stocks to Watch in August
  9. BioLineRx Announces Additional Investment From BVF Partners L.P.
  10. BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session
  11. BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer
  12. BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
  13. Top 10 Penny Stocks To Buy in 2017
  14. Corporate News Blog - Concordia Announces Review of Strategic Alternatives; Views Itself on the Auction Block to Repay its $3.5 billion Debt
  15. BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors
  16. BioLineRx Reports First Quarter 2017 Financial Results
  17. BioLineRx Makes Regulatory Submission for Trial of BL-8040
  18. BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML